Cancer Screening Market

Global Cancer Screening Market is valued at USD 155.26 Billion in 2022 and it is expected to reach USD 287.48 Billion by 2029 with a CAGR of 9.2% over the forecast period.

Global Cancer Screening Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2023-2029- Increasing incidences of cancer along with the high prevalence of risk factors and technological advancements in cancer screening are contributing to the growth and expansion of the cancer screening market worldwide.

Scope of Global Cancer Screening Market Report:

Cancer screening is a process that involves testing individuals who do not have any symptoms of cancer to detect the presence of cancer or precancerous cells early on. The goal of cancer screening is to identify cancer at an early stage when it is more treatable and curable.

The history of cancer screening dates to the 20^th century when it was discovered that early detection of cancer can improve the chances of successful treatment. The first cancer screening program was introduced in the 1930s for cervical cancer, and since then, several other screening programs have been developed for various types of cancer.

Today, cancer screening is widely used for several types of cancer, including breast, cervical, colon, lung, and prostate cancer. The screening tests used for each type of cancer may vary and generally involve imaging tests, blood tests, or physical exams.

The application of cancer screening is widespread in both the general population and individuals at high risk of developing cancer due to their age, family history, or lifestyle factors. For example; mammography is recommended for women aged 50-74 to detect breast cancer, while colonoscopy is recommended for individuals aged 50 and older to detect colon cancer.

Cancer screening's end users are healthcare practitioners such as primary care physicians and specialists, who use these procedures to order and interpret screening tests and offer necessary follow-up treatments.

Revenue generation model:

The revenue generation model in the cancer screening market typically involves the sale of screening tests and related products, such as diagnostic imaging equipment and biopsy instruments. Service revenue may also be generated through screening services provided by hospitals, clinics, and other healthcare providers.

Supply Chain Analysis:

The supply chain analysis in the cancer screening market typically involves multiple stages, including raw material suppliers, manufacturers of screening tests and related products, distributors, and end-users such as hospitals, clinics, and laboratories. The supply chain may also involve third-party logistics providers and regulatory agencies.

Value Chain Analysis:

The value chain model in the cancer screening market encompasses all the activities involved in creating and delivering value to the end user, including research and development, manufacturing, distribution, sales and marketing, and service and support. The value chain may also include regulatory compliance, quality control, and other support functions. Effective management of the value chain is critical for companies to remain competitive in the cancer screening market.

Covid-19 Impact on the Global Cancer Screening market:

The Covid-19 pandemic had a significant impact on the cancer screening market, and the impact was majorly negative.

Many healthcare facilities suspended non-essential services, including cancer screening programs, to minimize the risk of Covid-19 transmission and conserve medical resources for Covid-19 patients. The suspension of cancer screening programs led to a significant decline in cancer diagnoses, particularly for breast, cervical, and colon cancer. Delayed cancer diagnoses resulted in more advanced and difficult-to-treat cancers, leading to poorer outcomes and increased healthcare costs.

The pandemic also caused a shift in patient behavior, with many patients avoiding healthcare facilities due to fears of Covid-19 exposure. This avoidance resulted in a decrease in cancer screening rates and an increase in cancer-related deaths in the long term. Furthermore, the pandemic led to disruptions in the supply chain for cancer screening products, such as screening tests, medical devices, and imaging equipment, causing delays in the delivery of these products to healthcare facilities.

Key Players of Global Cancer Screening Market Report:

• Roche
• Quest Diagnostics
• Siemens Healthineers
• Hologic
• Abbott Laboratories
• Thermo Fisher Scientific
• Becton
• Dickinson and Company (BD)
• Qiagen
• Bio-Rad Laboratories
• F.Hoffmann-La Roche Ltd
• Exact Sciences Corporation
• Myriad Genetics
• Sysmex Corporation
• GE Healthcare
• Epigenomics AG
• Illumina
• Cancer Genetics Inc.
• Natera Inc.
• Agilent Technologies
• Invitae Corporation
• Cepheid
• Genomic Health
• Koninklijke Philips N.V.
• Toshiba Corporation
• BioNTech SE
• and others.

Global Cancer Screening Market Segmentation: -

By Test Type:

• Biomarker Tests

  • (Prostate-Specific Antigen) PSA Test
  • CEA (Carcinoembryonic Antigen) Test
  • Cancer Antigen 125 (CA 125) Test
  • Alpha-Fetoprotein (AFP) Test
  • Others

• Imaging Tests

  • Mammography
  • MRI
  • CT Scan
  • PET Scan
  • Ultrasound
  • Others

• Biopsy Tests

  • FNAB (Fine Needle Aspiration Biopsy)
  • CNB (Core Needle Biopsy)
  • Surgical Biopsy
  • Liquid Biopsy
  • Others

• Others

  • HPV Tests
  • Saliva Tests
  • Blood Tests
  • Others

By Cancer Type:

• Prostate Cancer
• Cervical Cancer
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Others

By Age Group:

• Below 30
• 30-50
• 50-65
• Above 65

By Gender:

• Male
• Female

By End User:

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Cancer Research Institutes
• Others

By Regional & Country Level:

• North America

  • US
  • Canada

• Europe

  • UK
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers:

Increasing Prevalence of Cancer:- Cancer is a leading cause of death worldwide, and the prevalence of cancer is increasing due to various factors such as an aging population, lifestyle factors, and environmental factors. According to the World Health Organization (WHO) estimates Cancer is the largest cause of mortality in the globe, accounting for over 10 million deaths in 2020, or roughly one in every six.

Given the increasing incidence of cancer worldwide, there is a growing demand for cancer screening services. As cancer is a potentially life-threatening disease, early detection and treatment are essential for successful outcomes. Governments and healthcare organizations are investing in cancer screening programs to increase the availability and accessibility of screening services. These efforts aim to ensure that individuals at high risk of developing cancer are identified early, leading to early intervention and better patient outcomes.

Increase in Cancer Risk Factors:- Lifestyle factors such as smoking, unhealthy diet, and lack of physical activity, as well as environmental factors such as pollution, are contributing to the increasing prevalence of cancer. Certain genetic factors and medical conditions also increase the risk of developing cancer. For example; a family history of cancer, certain genetic mutations, and chronic infections such as hepatitis B and C increases the risk of liver cancer. Similarly, human papillomavirus (HPV) infection increases the risk of cervical cancer.

For instance; according to WHO, tobacco use, high body mass index (BMI), consumption of alcohol, inadequate intake of fruits and vegetables, and a lack of physical activity account for almost one-third of cancer fatalities. As these risk factors continue to affect a growing proportion of the population, the need for cancer screening becomes more pressing.

Technological Advancements:- Technological advancements have been a significant driving force for the growth and expansion of the cancer screening market. These advancements have enabled the development of new and improved cancer screening tests and have improved the accuracy and efficiency of cancer screening.

One example of technological advancements in cancer screening is the development of liquid biopsy tests which use blood samples to detect cancer cells or tumor DNA, providing a less invasive and more convenient alternative to traditional biopsies. Molecular imaging is yet another example of technological advancement, that uses advanced imaging techniques such as PET and MRI scans to detect cancer cells and tumors in the body. Additionally, computer-aided detection software can analyze medical images and highlight potential areas of concern, improving the accuracy of cancer screening tests.

Market Restraints:

Lack of Awareness and Education:- Lack of awareness and education about cancer screening is a significant restraining factor for the cancer screening market. Despite efforts to increase public awareness, many individuals remain uninformed about the availability and benefits of cancer screening. This lack of awareness can lead to low screening rates and missed opportunities for early diagnosis and treatment, which can negatively impact patient outcomes.

Additionally, cultural and language barriers can further hinder communication and reduce awareness among underserved populations. Furthermore, there is ignorance and misperception regarding cancer screening among the general population, which leads to incorrect assumptions about the dangers and benefits of screening tests, as well as fear or anxiety about the screening process or prospective findings.

Cost of Cancer Screening:- The cost of cancer screening can be a barrier for many patients, particularly those without insurance or with high deductibles. Even when screening tests are covered by insurance, out-of-pocket costs for copays and deductibles can be a deterrent for some patients. It can vary depending on the type of test, the location of the screening facility, and the patient's insurance coverage. High screening costs can lead to low screening rates, particularly among underserved populations.

Market Opportunities:

Personalized Medicine: Advances in molecular and genetic testing have enabled personalized cancer screening, where the screening process is tailored to a patient's specific genetic profile. This presents an opportunity for companies to develop and market personalized cancer screening tests that can improve the accuracy and efficacy of cancer screening.

Artificial Intelligence (AI): AI-powered technologies have the potential to transform cancer screening by enabling faster, more accurate diagnosis and prediction of cancer. Companies can develop and market AI-powered cancer screening tools that can assist healthcare providers in early detection and diagnosis of cancer.

Market Trends:

Product and Technology Development:

Liquid biopsy: Liquid biopsy is a non-invasive method of cancer screening that detects circulating tumor cells or DNA in a patient's blood or other bodily fluids. This technology is gaining popularity due to its high sensitivity and specificity and has the potential to revolutionize cancer screening by providing early detection of cancer without the need for invasive procedures.

Artificial intelligence (AI): AI-powered technologies are being developed to assist in the early detection and diagnosis of cancer. These technologies can analyze medical imaging data, such as mammograms and CT scans, and identify potential cancerous lesions or abnormalities that may be missed by human interpretation.

Customer Trends:

Increased demand for Non-Invasive Screening Methods: Patients are increasingly seeking non-invasive cancer screening methods that are less painful and less invasive than traditional screening methods. This trend is driving the development of liquid biopsy and other non-invasive screening technologies.

Growing Interest in Genetic Testing: Patients are increasingly interested in genetic testing to assess their risk of developing cancer and to inform their cancer screening and treatment decisions. This trend is driving the development of more sophisticated genetic testing technologies and the integration of genetic testing into cancer screening and treatment plans.

Market Competition Nature:

Competition in the cancer screening market is intense, with several key players vying for market share. These players compete based on factors such as product innovation, pricing, distribution channels, and strategic partnerships. The market is highly fragmented, with several small and medium-sized players competing alongside larger, established players.

• For example; in 2018, Roche acquired Foundation Medicine, a leader in genomic profiling of cancer, to strengthen its position in personalized healthcare.
• Quest Diagnostics had also pursued acquisitions, such as its acquisition of Oxford Immunotec in 2018, to expand its portfolio of diagnostic services.
• In 2020, Thermo Fisher Scientific announced plans to expand its operations in the Asia-Pacific region to capitalize on the growing demand for cancer screening in emerging markets.
• Other companies, such as Hologic and Siemens Healthineers, have focused on product innovation, developing new imaging technologies and molecular diagnostic tests for cancer screening.

Overall, the cancer screening market is expected to remain highly competitive, with market players continuing to invest in innovative products and strategic partnerships to gain a competitive edge.

Geography Analysis:

North America:

The high prevalence of risk factors and technological advancements are majorly driving the cancer screening market in North America. The North American region has a high prevalence of risk factors associated with cancer, such as tobacco use, obesity, and physical inactivity. These risk factors increase the likelihood of developing cancer, and early detection is key to improving patient outcomes and reducing the burden of cancer. For instance; in the U.S., Cancer is the second highest cause of death.

Tobacco use is one of the most significant risk factors for cancer in North America. Smoking is a major cause of lung cancer, as well as other types of cancer such as bladder, kidney, and throat cancer. As reported by the CDC in the United States, smoking and secondhand smoke cause 80% to 90% of lung cancer fatalities, and approximately 34 million individuals in the United States smoke cigarettes. Obesity and physical inactivity are also major risk factors for several types of cancer, including breast, colorectal, and endometrial cancer.

Additionally, North America is a leader in healthcare innovation and technological advancements in cancer screening, particularly in the development of new imaging techniques and minimally invasive screening tests. Advances in molecular and genetic testing, imaging technologies, artificial intelligence, and machine learning, and minimally invasive procedures have all contributed to the growth of the cancer screening market. This has led to the introduction of more accurate and efficient screening tests, improving patient outcomes, and reducing the burden of cancer.

Europe:

Increasing incidence of cancer and government support for cancer screening are increasing the demand for cancer screening tests and services in Europe. The incidence of cancer in Europe has been steadily increasing, with the aging population being a significant contributor to this trend.

As people age, their likelihood of developing cancer increases due to changes in their cells and increased exposure to environmental factors that can damage their DNA. In addition to the aging population, lifestyle factors such as smoking, poor diet, and lack of exercise also contribute to the rising incidence of cancer.

As reported by the European Commission, individuals aged 65 and older accounted for 60% of the projected diagnoses and 73% of the estimated deaths in 2020. Moreover, the experts also analyzed that population aging would result in a 32% rise in the number of cancer deaths by 2040 in comparison to 2020.

Additionally, many European governments have implemented national cancer screening programs to improve the availability and accessibility of cancer screening tests for their populations.

For instance; the United Kingdom has implemented screening programs for breast, cervical, and colorectal cancer, while France has a national colorectal cancer screening program for individuals aged 50-74. These programs often target high-risk groups, such as those with a family history of cancer or specific demographic groups, to maximize the impact of screening efforts.

Key Benefits of Global Cancer Screening Market Report–

• Global Cancer Screening Market report covers in-depth historical and forecast analysis.
• Global Cancer Screening Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Cancer Screening Market report helps to identify opportunities in the marketplace.
• Global Cancer Screening Market report covers extensive analysis of emerging trends and competitive landscape.